Comparative Pharmacology
Head-to-head clinical analysis: ACHROMYCIN V versus OXYTETRACYCLINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACHROMYCIN V versus OXYTETRACYCLINE HYDROCHLORIDE.
ACHROMYCIN V vs OXYTETRACYCLINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bacteriostatic; binds reversibly to 30S ribosomal subunit, inhibits protein synthesis by blocking aminoacyl-tRNA binding to mRNA-ribosome complex.
Oxytetracycline binds reversibly to the 30S ribosomal subunit, inhibiting protein synthesis by blocking the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
250-500 mg orally every 6 hours
250-500 mg orally every 6 hours or 1-2 g/day divided every 12 hours intravenously.
None Documented
None Documented
Terminal elimination half-life is 6-12 hours in patients with normal renal function; prolonged in renal impairment (up to 48-72 hours in anuria).
6-10 hours (prolonged to 48-100 hours in renal impairment; consider dose adjustment in CrCl <50 mL/min)
Renal (60% unchanged in urine via glomerular filtration), biliary/fecal (40% as active drug and metabolites, with a portion undergoing enterohepatic recirculation).
Renal (60-70% unchanged by glomerular filtration); biliary/fecal (20-35%)
Category C
Category D/X
Tetracycline Antibiotic
Tetracycline Antibiotic